No Data
No Data
[Brokerage Focus] Huaan securities first initiated a "buy" rating on CMS (00867), bullish on its performance recovery after the concentrated listing of innovative products.
Golden Finance News | Huaan Securities issued a research report, stating that CMS (00867) is an open platform enterprise that connects pharmaceutical innovation with commercialization, and manages the entire life cycle of products. In recent years, the company has gradually transformed from a single agency operation model to an innovative drug enterprise, obtaining exclusive licensing rights for innovative drugs in China and authorized countries or regions, including clinical development, production, registration, and sales through private equity investment, strategic cooperation, or independent research. The bank pointed out that since 2018, the national organized drug centralized volume procurement has been carried out in nine batches. The ninth batch of centralized procurement has introduced new regulations regarding the purchase cycle of winning bidders for pharmaceutical products.
The Three-year Loss for China Medical System Holdings (HKG:867) Shareholders Likely Driven by Its Shrinking Earnings
cms (00867.HK): Application for the market approval of phosphorus luconitib cream (vitiligo indication) has been accepted by the National Medical Products Administration.
Gelonghui September 23 | CMS Pharmaceutica (00867.HK) announced that the new drug application (NDA) for phosphorus retinamide cream (vitiligo indication) has been accepted by the China National Medical Products Administration (NMPA) on September 24, 2024. Retinamide cream has achieved positive results in real-world studies in China. The proportion of patients achieving F-VASI75 at the 24th week in the treatment group reached 49.5%, significantly higher than the target value of 14.1% (P<0.0001), achieving the main endpoint, proving that retinamide cream can effectively treat non-segmental vitiligo.
Express News | China Medical System Holdings - New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted by Nmpa
Intelligent Transportation Hong Kong Shareholder Equity Disclosure | September 20th
Hong Kong Stock Shareholder Equity Disclosure | September 20th
VasQ Extravascular Support Granted Transitional Pass-Through (TPT) Payment
No Data
No Data